Citizens JMP raised the firm’s price target on Precigen (PGEN) to $8 from $6 and keeps an Outperform rating on the shares. Precigen discussed the approval of PAPZIMEOS for the treatment of respiratory papillomatosis, as well as the price, with a wholesale acquisition cost of $460k per patient, higher than the firm’s prior assumption of $200k per patient, the analyst tells investors in a research note.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PGEN:
- Precigen Enters Commercial Supply Agreement with Catalent
- Unusually active option classes on open August 18th
- Precigen’s PAPZIMEOS Receives FDA Approval for RRP
- Morning News Wrap-Up: Friday’s Biggest Stock Market Stories!
- Precigen Stock (PGEN) Roars Over 60% Higher on FDA Green Light for Papzimeos Therapy